Monitoring Bulky Mediastinal Disease with Gallium-67, CT-Scan and Magnetic Resonance Imaging in Hodgkin's Disease and High-Grade Non-Hodgkin's Lymphoma

References

• Jochelson M., Mauch P., Balikian J., Rosenthal D., Canellos G. The significance of the residual mediastinal mass in treated Hodgkin's disease. J. Clin. Oncol. 1988; 3: 634–640
   Google Scholar
• Khoury M.B., Godwin J.D., Halvorsen R., et al. Role of the chest CT in non-Hodgkin lymphoma. Radiology 1986; 158: 659–662
   PubMed Web of Science ®Google Scholar
• Radford J.A., Cowan R.A., Flanagan M., et al. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. J. Clin. Oncol. 1988; 6: 940–946
   PubMed Web of Science ®Google Scholar
• Klimo P., Connors J.M. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann. Intern. Med. 1985; 102: 596–602
   PubMed Web of Science ®Google Scholar
• Fisher R.I., Gaynor E.R., Dahlberg S., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Mazza P., Zinzani P.L., Martelli M., et al. MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas. Leuk. Lymphoma 1995; 16: 657–663, (In Press) 20(314): 1995
   Web of Science ®Google Scholar
• Tura S., Mazza P., Gherlinzoni F., et al. High-dose therapy followed by autologous bone marrow transplantation (ABMT) in previously untreated non-Hodgkin's lymphoma. Scand. J. Haematol. 1986; 37: 347–352
   PubMedGoogle Scholar
• Canellos G.P., Nadler L., Takvorian T. Autologous bone marrow transplantation in the treatment of malignant lymphoma and Hodgkin's disease. Semin. Hematol. 1988; 25(suppl 2)58–65
   PubMed Web of Science ®Google Scholar
• Gherlinzoni F., Martelli M., Mazza P., et al. Autologous bone marrow transplantation (ABMT) vs DHAP in aggressive non-Hodgkin's lymphomas (NHL) partially responding to first-line chemotherapy. Blood 1994; 84(suppl 1)234a
   Google Scholar
• Zinzani P.L., Mazza P., Gherlinzoni F., et al. Massive mediastinal involvement in stage I-II Hodgkin's disease: response to combined modality treatment. Leuk. Lymphoma 1992; 8: 81–85
   PubMed Web of Science ®Google Scholar
• Tura S., Canellos G.P., Goldstone A., et al. Hodgkin's disease: controversies and challenges for the future. Haematologica 1991; 76: 63–79
   PubMedGoogle Scholar
• Longo D.L., Russo A., Duffey P.L., et al. Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case of combined modality treatment. J. Clin. Oncol. 1991; 9: 227–235
   PubMed Web of Science ®Google Scholar
• The International non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N. Engl. J. Med. 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Lewis E., Bernardino M.E., Salvador P.G., et al. Post therapy CT detected mass in lymphoma patients. Is it viable tissue?. J. Comput. Assist. Tomogr. 1982; 6: 792–796
   PubMed Web of Science ®Google Scholar
• Russell K.J., Hoppe R.T. Response of mediastinal Hodgkin's disease to radiotherapy: rate of tumor regression not predictive of outcome. Int. J. Radiat. Oncol. Biol. Phys. 1989; 16: 201–204
   PubMed Web of Science ®Google Scholar
• Canellos G.P. Residual mass in lymphoma may not be residual disease. J. Clin. Oncol. 1988; 6: 931–933
   PubMed Web of Science ®Google Scholar
• Kaplan W.D., Jochelson M.S., Herman T.S., et al. Gallium-67 imaging: a predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma. J. Clin. Oncol. 1990; 8: 1966–1970
   PubMed Web of Science ®Google Scholar
• Front D., Israel O., Epelbaum R., et al. Ga-67 SPECT before and after treatment of lymphoma. Radiology 1990; 175: 515–519
   PubMed Web of Science ®Google Scholar
• Front D., Ben-Haim S., Israel O., et al. Lymphoma: predictive value of Ga-67 scintigraphy after treatment. Radiology 1992; 182: 359–363
   PubMed Web of Science ®Google Scholar
• Cooper D.L., Caride V.J., Zloty M., Germino J., Farber L.R., Hoffer P.B. Gallium scans in patients with mediastinal Hodgkin's disease treated with chemotherapy. J. Clin. Oncol. 1993; 11: 1092–1098
   PubMed Web of Science ®Google Scholar
• King S.C., Reiman R.J., Prosnitz L.R. Prognostic importance of restaging Gallium scans following induction chemotherapy for advanced Hodgkin's disease. J. Clin. Oncol. 1994; 12: 306–311
   PubMed Web of Science ®Google Scholar
• Janicek M., Kaplan W., Neuberg D., Canellos G.P., Shulman L., Shipp M.A. Early restaging Gallium scans identify durable responses to induction therapy in high risk patients with aggressive non-Hodgkin's lymphoma (NHL). Blood 1994; 84(suppl 1)233a
   Google Scholar
• Nyman R.S., Rehn S.M., Glimelius B. L. G., Hagberg H.E., Hemmingsson A.L., Jung B. Magnetic resonance imaging for assessment of treatment effects in mediastinal Hodgkin's disease. Acta Radiologica 1987; 28: 145–151
   PubMed Web of Science ®Google Scholar
• Nyman R.S., Rehn S.M., Glimelius B. L. G., Hagberg H.E., Hemmingsoon A.L., Sundstrom C.J. Residual mediastinal masses in Hodgkin's disease: prediction of size with MR imaging. Radiology 1989; 170: 435–440
   PubMed Web of Science ®Google Scholar
• Tesoro-Tess J.D., Balzarini L., Ceglia E., Petrillo R., Santoro A., Musumeci R. Magnetic resonance imaging in the initial staging of Hodgkin's disease and non-Hodgkin lymphoma. Eur. J. Radiol. 1991; 12: 81–90
   PubMed Web of Science ®Google Scholar
• Rahmouni A., Tempany C., Jones R., Mann R., Yang A., Zerhouni E. Lymphoma: monitoring tumor size and signal intensity with MR imaging. Radiology 1993; 188: 445–451
   PubMed Web of Science ®Google Scholar
• Gasparini M.D., Balzarini L., Castellani M.R., et al. Current role of gallium scan and magnetic resonance imaging in the management of mediastinal Hodgkin lymphoma. Cancer 1993; 72: 577–582
   PubMed Web of Science ®Google Scholar
• Hill M., Cunningham D., MacVicar D., et al. Role of magnetic resonance imaging in predicting relapse residual masses after treatment of lymphoma. J. Clin. Oncol. 1993; 11: 2273–2278
   PubMed Web of Science ®Google Scholar
• Foss Abrahamsen A., Lien H.H., Aas M., et al. Magnetic resonance imaging and 67Gallium scan in mediastinal malignant lymphoma: a retrospective pilot study. Ann. Oncol. 1994; 5: 433–436
   PubMed Web of Science ®Google Scholar
• Stansfeld A.G., Diebold J., Kapanci Y., et al. Updated Kiel classification for lymphomas. Lancet 1988; i: 292–293
   Google Scholar
• Oken M., Creech R., Tormey D. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 1982; 5: 649–655
   PubMed Web of Science ®Google Scholar
• Bonadonna G., Zucali R., De Lena M., Valagussa P. Combined chemotherapy (MOPP or ABVD)-radiotherapy approach in advanced Hodgkin's disease. Cancer Treat. Rep. 1977; 61: 769–777
   PubMedGoogle Scholar
• Guglielmi C., Amadori S., Anselmo A.P., et al. Sequential combination chemotherapy of high grade non-Hodgkin's lymphoma with 5-fluoouracil, methotrexate, cytosine-arabinoside, cytosine lophos-phamide, doxorubicin, vincristine and prednisone (F-MACHOP). Cancer Invest. 1987; 5: 159–169
   PubMed Web of Science ®Google Scholar
• Zinzani P.L., Barbieri E., Visani G., et al. Ifosfamide, epirubicin, and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease. Haematologica 1994; 79: 508–512
   PubMed Web of Science ®Google Scholar
• Wahl R.L., Quint L.E., Cieslak R.D., Aisen A.M., Koeppe R.A., Meyer C.R. Anatometabolic tumor imaging: fusion of FDG-PET with CT or MRI to localize foci of increased activity. J. Nucl. Med. 1993; 34: 1190–1197
   PubMed Web of Science ®Google Scholar
• Newman J.S., Francis I.R., Kaminski M.S., Wahl R.L. Imaging of lymphoma with PET with 2-(F-18)-Fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994; 190: 111–116
   PubMed Web of Science ®Google Scholar